Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Bal

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Leukemia|August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLuciano J Costa, Benjamin A Derman, Susan Bal, et al.
Transplantation and Cellular Therapy|December 9, 2022
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN TrialsSaurabh Chhabra, Natalie Callander, Nicole L Watts, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
Blood Advances|July 2, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell LeukemiaMahmoud R Gaballa, Kelley Julian, Aimaz Afrough, et al.
Transplantation and Cellular Therapy|January 26, 2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant ResearchHemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Leukemia|August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLuciano J Costa, Benjamin A Derman, Susan Bal, et al.
Transplantation and Cellular Therapy|December 9, 2022
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN TrialsSaurabh Chhabra, Natalie Callander, Nicole L Watts, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
Blood Advances|July 2, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell LeukemiaMahmoud R Gaballa, Kelley Julian, Aimaz Afrough, et al.
Transplantation and Cellular Therapy|January 26, 2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant ResearchHemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, et al.
Pageof 7